We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law and policy, copyright, and trade.
Some highlights from the issue:
- A chapter outlining the disruptions faced by conventional biopharma IP strategies and the current AI drug development landscape, including identifying trends on how AI-focused firms are currently allocating resources to assets, specific targets or modalities, and/or underlying AI technologies;
- A study examining how direct exposure to traumatic shocks shapes the trajectory of local inventive activity in the United States from 1995 to 2022; and
- A paper investigating the economic impact of Intellectual property rights (IPRs) in the context of complementary vertical innovation by firms in upstream and downstream industries.
To download the newsletter click here.
